Concordance among four commercially available, validated programmed cell death ligand-1 assays in urothelial carcinoma

• Main Authors: Magdalena Zajac (Author), Marietta Scott (Author), Marianne Ratcliffe (Author), Paul Scorer (Author), Craig Barker (Author), Hytham Al-Masri (Author), Marlon C. Rebelatto (Author), Jill Walker (Author)
• Format: Book
• Published: BMC, 2019-09-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract Background Antibodies targeting the programmed cell death-1 (PD-1)/PD-ligand 1 (PD-1/PD-L1) checkpoint have shown promising clinical activity in patients with advanced urothelial carcinoma (UC). Expression of PD-L1 in UC tumors has been investigated using different antibody clones, staining...